Skip to main content

Table 5 Least square mean changes in total cholesterol, high-density lipoprotein cholesterol and triglyceride from baseline after 8 weeks of treatment

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

 

Summary of each treatment

FMS/RSV vs. FMS

FMS/RSV vs. RSV

 

FMS/RSV

(N = 46)

FMS

(N = 45)

RSV

(N = 44)

LSM difference (SE)

P-valuea

LSM difference (SE)

P-valuea

Total cholesterol

−36.13 (1.77)

−3.62 (1.92)

−35.99 (1.95)

−32.51 (2.44)

 

−0.14 (2.45)

 

 95% CI

(−39.63, −32.64)

(−7.41, 0.17)

(−39.86, −32.13)

(−37.34, −27.69)

<0.001

(−4.99, 4.71)

0.954

HDL-C

10.24 (2.63)

−3.22 (2.86)

13.43 (2.95)

13.47 (3.63)

 

−3.19 (3.67)

 

 95% CI

(5.03, 15.45)

(−8.88, 2.43)

(7.60, 19.26)

(6.28, 20.65)

<0.001

(−10.46, 4.08)

0.387

Triglyceride

−12.78 (5.79)

20.30 (6.27)

−13.65 (6.41)

−33.08 (7.97)

 

0.88 (8.06)

 

 95%CI

(−24.24, −1.32)

(7.89, 32.71)

(−26.34, −0.96)

(−48.86, −17.30)

<0.001

(−15.08, 16.83)

0.914

  1. HDL-C high-density lipoprotein cholesterol, FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LSM least square mean, SE standard error
  2. aComparison between the combination therapy and monotherapy was analyzed by ANCOVA model adjusted for baseline values, age, gender and smoking status
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us